EUVIMEDEUVIMED entdecken
Übersichtsarbeit

The risk of chronic psychedelic and MDMA microdosing for valvular heart disease

Michael Tagen iD, Daniel Mantuani, Liron van Heerden, Alex Holstein, Linda E Klumpers iD, Richard Knowles

Journal of Psychopharmacology · 2023

DOI: 10.1177/02698811231190865 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Psychopharmacology, 2023. Verfasst von Michael Tagen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Verdient Science LLC, Englewood, CO, USA. Hauptthemen laut MEDLINE: Hallucinogens, N-Methyl-3,4-methylenedioxyamphetamine, Heart Valve Diseases. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 148 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Psychedelic microdosing is the practice of taking very low doses of psychedelic substances, typically over a longer period of time. The long-term safety of chronic microdosing is relatively uncharacterized, but valvular heart disease (VHD) has been proposed as a potential risk due to activation of the serotonin 5-HT 2B receptor. However, this risk has not yet been comprehensively assessed. This analysis searched for all relevant in vitro, animal, and clinical studies related to the VHD risk of lysergic acid diethylamide (LSD), psilocybin, mescaline, N,N-dimethyltryptamine (DMT), and the non-psychedelic 3,4-methylenedioxymethamphetamine (MDMA). All five compounds and some metabolites could bind to the 5-HT 2B receptor with potency equal to or greater than that of the 5-HT 2A receptor, the primary target of psychedelics. All compounds were partial agonists at the 5-HT 2B receptor with the exception of mescaline, which could not be adequately assessed due to low potency. Safety margins relative to the maximum plasma concentrations from typical microdoses were greater than known valvulopathogens, but not without potential risk. No animal or clinical studies appropriately designed to evaluate VHD risk were found for the four psychedelics. However, there is some clinical evidence that chronic ingestion of full doses of MDMA is associated with VHD. We conclude that VHD is a potential risk with chronic psychedelic microdosing, but further studies are necessary to better define this risk.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HallucinogensN-Methyl-3,4-methylenedioxyamphetamineHeart Valve DiseasesHumansMescalineSerotoninPsilocybinLysergic Acid Diethylamide

Stichwörter der Autor:innen

Psychedelicsmicrodosingvalvular heart disease

Substanzen

HallucinogensN-Methyl-3,4-methylenedioxyamphetamineMescalineSerotoninPsilocybinLysergic Acid Diethylamide

Autor:innen und Institutionen

  • Verdient Science LLC, Englewood, CO, USA.
  • Delos Psyche Research Group, Mountain View, CA, USA.
  • Delos Therapeutics, Mountain View, CA, USA.
  • Larner College of Medicine, University of Vermont, Burlington, Vermont, USA.

ORCID-Profile: Michael Tagen, Linda E Klumpers

Zitieren

APA

Tagen, M., Mantuani, D., van Heerden, L., Holstein, A., Klumpers, L. E., & Knowles, R. (2023). The risk of chronic psychedelic and MDMA microdosing for valvular heart disease. Journal of Psychopharmacology. https://doi.org/10.1177/02698811231190865

Vancouver

Tagen M, Mantuani D, van Heerden L, Holstein A, Klumpers LE, Knowles R. The risk of chronic psychedelic and MDMA microdosing for valvular heart disease. Journal of Psychopharmacology. 2023. doi:10.1177/02698811231190865

BibTeX
@article{Tagen2023,
  author = {Tagen, Michael and Mantuani, Daniel and van Heerden, Liron and Holstein, Alex and Klumpers, Linda E and Knowles, Richard},
  title = {The risk of chronic psychedelic and MDMA microdosing for valvular heart disease},
  journal = {Journal of Psychopharmacology},
  year = {2023},
  doi = {10.1177/02698811231190865}
}
Kostenlos starten →